Polaprezinc
Polaprezinc is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| digestive system diseases | D004066 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| promacta | New Drug Application | 2025-06-06 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
52 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | — | 1 | 1 | 2 |
| Peptic esophagitis | D004942 | EFO_1001095 | — | — | — | — | 1 | 1 | 2 |
| Hyperuricemia | D033461 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | 1 | — | 1 | 2 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | — | — | 1 |
| Periodontal index | D010512 | — | — | — | — | 1 | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 1 | — | — | 1 |
| Male breast neoplasms | D018567 | — | — | — | — | 1 | — | — | 1 |
| Deglutition disorders | D003680 | — | R13.1 | — | — | 1 | — | — | 1 |
| Adjuvant radiotherapy | D018714 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Peripheral arterial disease | D058729 | EFO_0004265 | — | 2 | 4 | — | — | — | 4 |
| Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | 2 | 4 | — | — | — | 4 |
| Hyperglycemia | D006943 | — | R73.9 | — | 1 | — | — | 1 | 2 |
| Peripheral nervous system diseases | D010523 | — | G64 | 1 | 1 | — | — | 1 | 2 |
| Syndrome | D013577 | — | — | — | 1 | — | — | 1 | 2 |
| Persian gulf syndrome | D018923 | EFO_0007430 | — | — | 1 | — | — | 1 | 2 |
| Aging | D000375 | GO_0007568 | R41.81 | — | 1 | — | — | — | 1 |
| Heart disease risk factors | D000082742 | — | — | — | 1 | — | — | — | 1 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | 1 | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | 2 | 3 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 4 | 4 |
| Exercise | D015444 | EFO_0000483 | — | — | — | — | — | 3 | 3 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | — | — | 2 | 2 |
| Sclerosis | D012598 | — | — | — | — | — | — | 2 | 2 |
| Dietary supplements | D019587 | — | — | — | — | — | — | 2 | 2 |
| Xerostomia | D014987 | — | K11.7 | — | — | — | — | 2 | 2 |
| Oxidative stress | D018384 | EFO_1001905 | — | — | — | — | — | 2 | 2 |
| Fatigue | D005221 | — | R53.83 | — | — | — | — | 2 | 2 |
| Overweight | D050177 | — | E66.3 | — | — | — | — | 2 | 2 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | — | — | 2 | 2 |
Show 48 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Polaprezinc |
| INN | polaprezinc |
| Description | Carnosine is a dipeptide that is the N-(beta-alanyl) derivative of L-histidine. It has a role as an anticonvulsant, an antioxidant, an antineoplastic agent, a human metabolite, a Daphnia magna metabolite, a mouse metabolite, a neuroprotective agent and a geroprotector. It is a conjugate acid of a carnosinate. It is a tautomer of a carnosine zwitterion. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NCCC(=O)N[C@@H](Cc1c[nH]cn1)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 305-84-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL242948 |
| ChEBI ID | 15727 |
| PubChem CID | — |
| DrugBank | DB11695 |
| UNII ID | 0WA1B15A1Z (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Promacta – Ligand Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Promacta – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,807 documents
View more details
Safety
Black-box Warning
Black-box warning for: Promacta
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
15,663 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use